Research and development costs of Enhua pharmaceutical industry will increase steadily in the future
-
Last Update: 2014-09-12
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the person, R & D investment should be in line with the company's development and will be increased gradually according to the plan "If there is a variety like a new drug, we will certainly do it at a high price, but there is no such variety yet." In terms of variety selection, the person said that the company's R & D scope has always focused on spiritual and neurological products In addition, in addition to the research and development of generic drugs, the company is also carrying out some changes in the new indications and dosage forms of old drugs Enhua pharmaceutical is a leading drug manufacturer in the field of central nervous system in China, and the proportion of R & D expenses in operating revenue of the company is lower than that of similar pharmaceutical enterprises In 2013, the company invested 46.24 million yuan in scientific research funds, accounting for only 2.07% of the operating revenue in 2013
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
